The EPS beat reflects cost management or lower-than-expected losses, but with near-zero revenue, fundamentals remain pre-commercial. The ASCO abstract acceptance is a credibility milestone that may boost investor sentiment ahead of clinical trial updates. Monitor enrollment progress in the U.S. IMPACT trial and any future revenue inflection as key catalysts.
Price Chart
Executive Summary
Alpha Tau Medical announced abstract acceptance of pooled clinical data from 58 pancreatic cancer patients at the 2026 ASCO Annual Meeting, a prestigious oncology conference. The company also reported Q4 2025 earnings with an EPS of $-0.08, beating consensus by 35.3%, though revenue was minimal at $66K. The ASCO recognition signals growing scientific validation for its Alpha DaRT therapy.
Key Financial Metrics
Key Facts
- Q4 2025 EPS: $-0.08 (consensus: $-0.12), representing a 35.3% beat
- Revenue: $66K (in line with estimates)
- Abstract on Alpha DaRT for pancreatic cancer accepted at ASCO 2026 Annual Meeting
- Data pooled from 58 patients across three clinical studies in Canada and Israel
- ASCO is the world's largest and most prestigious oncology conference
- Forward-looking commentary on U.S. IMPACT and French ACAPELLA trials ongoing
Financial Impact
EPS loss narrowed by $0.04 YoY (from $-0.14 to $-0.08), revenue remains negligible at $66K
Risk Factors
- Company remains pre-revenue with significant ongoing losses
- Clinical data is preliminary and may not predict final trial outcomes
- Heavy reliance on successful regulatory approval and future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281701 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access